IFM Investors Pty Ltd Sells 2,329 Shares of Pfizer Inc. $PFE

IFM Investors Pty Ltd trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,085,880 shares of the biopharmaceutical company’s stock after selling 2,329 shares during the quarter. IFM Investors Pty Ltd’s holdings in Pfizer were worth $27,516,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of PFE. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Triumph Capital Management boosted its position in Pfizer by 20.0% during the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 1,717 shares during the last quarter. Gotham Asset Management LLC boosted its position in Pfizer by 333.4% during the fourth quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company’s stock valued at $3,742,000 after acquiring an additional 108,494 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in Pfizer by 80.7% during the fourth quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company’s stock valued at $25,434,000 after acquiring an additional 427,886 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. HSBC cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Finally, Jefferies Financial Group increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Stock Performance

PFE opened at $24.74 on Wednesday. The company’s fifty day moving average price is $24.85 and its two-hundred day moving average price is $24.33. The company has a market cap of $140.66 billion, a price-to-earnings ratio of 13.16, a PEG ratio of 0.87 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.